← FDA DRUG APPROVALS

FDA ANDA · ANDA076871

MITOXANTRONE

Sponsor: HOSPIRA

APPLICATION
ANDA076871
TYPE
ANDA
ORIGINAL APPROVAL
2006-04-11
LATEST ACTION
2017-03-24
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

MITOXANTRONE HYDROCHLORIDEPrescription
MITOXANTRONE HYDROCHLORIDE EQ 30MG BASE/15ML (EQ 2MG BASE/ML) · INJECTABLE · INJECTION
MITOXANTRONE HYDROCHLORIDEPrescription
MITOXANTRONE HYDROCHLORIDE EQ 20MG BASE/10ML (EQ 2MG BASE/ML) · INJECTABLE · INJECTION
MITOXANTRONE HYDROCHLORIDEPrescription
MITOXANTRONE HYDROCHLORIDE EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) · INJECTABLE · INJECTION

Approval history

2017-03-24Manufacturing (CMC) · Supplement 14 · unknownAP
2015-01-30Manufacturing (CMC) · Supplement 12 · unknownAP
2014-12-05Labeling · Supplement 9 · standardAP
2012-11-13Labeling · Supplement 8AP
2009-08-20Labeling · Supplement 6AP
2009-08-20Labeling · Supplement 5AP
2006-04-11OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →